Xpovio (selinexor) for glioblastoma – pro
Multiple trials of this drug in combinaitons or alone in similar setting s to that of the patient are listed at https://www.cancer.gov/research/participate/clinical-trials/intervention/selinexor
Selinexor, an oral medication, inhibits exportin-1 (XPO-1), a major exporter of proteins from the nucleus to cytoplasm that is overexpressed in many cancers, including glioblastoma. Exportin inhibition results in retention of various tumor suppressor proteins in the nucleus, inducing reactivation of tumor suppressor function as well as other antineoplastic effects. Selinexor was approved by the FDA for the treatment of refractory multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma and had pre-clinical activity against glioblastoma models.
assman AB, Wen PY, van den Bent MJ, Plotkin SR, Walenkamp AME, Green AL, Li K, Walker CJ, Chang H, Tamir S, Henegar L, Shen Y, Alvarez MJ, Califano A, Landesman Y, Kauffman MG, Shacham S, Mau-Sørensen M. A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma. Clin Cancer Res. 2022 Feb 1;28(3):452-460.
Yasmin Odia et al, A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma. Meeting Abstract: 2021 ASCO Annual Meeting I
Central Nervous System Tumors May 28, 2021
Xpovio Prescribing Information 2024